Post Logic

Post-Logic Therapeutics is a pre-clinical stage biotechnology company focused on deciphering and drugging the "post-transcriptional logic" of the cell. Founded by renowned Stanford University researchers Howard Chang and Daniel Herschlag, the company targets RNA-binding proteins (RBPs) to modulate gene expression at the RNA level. By leveraging deep insights into RNA biology and protein-RNA interactions, Post-Logic aims to develop a new class of small molecule therapeutics for hard-to-treat diseases, including cancer and rare genetic disorders. The company is backed by prominent venture capital firms such as ARCH Venture Partners and Foresite Capital. Its approach represents a shift from traditional RNA-targeting methods toward sophisticated modulation of the regulatory networks that govern RNA fate and function.